According to a recent market study published by Growth Market Reports, titled, “Global Radiation Injury Drugs market by exposure, by source, by diagnosis, by treatment, by route of administration, and by application: Size, Share, Trends and Opportunity Analysis, 2020-2028”, the global radiation injury drugs market was valued at USD 565.6 million in 2020 and is projected to reach USD 747.9 million by 2028, expanding at a CAGR of 3.7% during the forecast period.
Request a free sample copy @ https://growthmarketreports.com/request-sample/2723
Based on exposure the global radiation injury drugs market is segmented into internal exposure and external exposure. Based on source the global radiation injury drugs market is segmented into background radiation and man-made radiation. Based on diagnosis the global radiation injury drugs market is segmented into lymphocytes count, geiger-muller counter, and blood test and dosimeter.
Based on treatment the global radiation injury drugs market is segmented into treatment for radiation sickness, treatment for internal contamination, and others. Based on route of administration the global radiation injury drugs market is segmented into oral and parenteral. Based on application the global radiation injury drugs market is segmented into ambulatory surgery centers (ASCs), hospitals, research institutes, and others.
Lack of patient awareness about the adverse effects of radiation therapy is expected to stymie the expansion of the radiation injury drugs market. The value of RT in cancer management is underappreciated by the general public. According to a survey on public awareness of RT in the UK, just 10% of individuals were aware that treatment cures a high percentage of cancers, and over 40% expressed negative attitude against it. Information from the media, such as linkages to nuclear power plant accidents, nuclear weapons, and secondhand experiences, exacerbates these negative attitudes. These negative attitudes enhance RT anxiety, which contribute to a delay in seeking therapy or refusal of treatment.
New radiation therapies for cancer therapy with few side effects are expected to slow the expansion of the radiation injury drugs market. When cancer cells die or when the energy from the radiation beam affects healthy tissue near the tumor, radiation treatment causes side effects. Radiation treatment is expected to affect less healthy tissue and have fewer side effects than traditional radiation therapy, as doctors are able to control where the maximum concentration of energy is released. Some of the energy released by radiation treatment is released in healthy tissue. The side effects are determined by the area of the body being treated and the radiation therapy dose received.
As per Growth Market Reports industry analyst, Divyanka Sankhe, “Radiation Injury Drugs are expected to be popular among end-users during the forecast period. Major factors propelling the Radiation Injury Drugs Market are growing technological advancements in Radiation Injury Drugs, rising demand for Radiation Injury Drugs technology, and increasing incidence of cancers.
Major market players in almost every industry rely on the development of new and innovative products. Companies are focusing on investment for technologically advanced products and product development. Increasing expenditure on advancement of technology is leading to development of products. Rising development of healthcare infrastructure is expected to drive the market. Moreover, growing investment in healthcare infrastructure by various countries is positively affecting the market growth. Companies in almost every industry rely on research and development (R&D) to plan, design, and deliver new and innovative products and are focusing on advancement and research trends in the Radiation Injury Drugs Market. Many initiatives are taken by governments for encouraging the usage of radiation injury drugs. In developing countries, governments are continuously funding for improving quality and efficiency of radiation injury drugs, which is estimated to drive the market.”
Key Takeaways from the Study
- The North America segment held 42.2% value share of the market in 2020. The segment is projected to account for the largest share of the market during the forecast period.
- The Europe segment is anticipated to expand at a lucrative CAGR of 3.9% between 2021 and 2028. The segment is projected to account for the largest share of the market during the forecast period.
- Key players in the global radiation injury drugs market are Eli Lilly and Company, Teva Pharmaceutical, Amgen Inc, La Jolla Pharmaceutical Co, Novartis, Johnson & Johnson, Heyl Chemisch-pharmazeutische Fabrik.
- In terms of value, The Internal Exposure segments are expected to lose 36.1 BPS respectively, during the forecast period. However, the External Exposure segment is anticipated to gain 36.1 BPS respectively, during the forecast period.
Report Scope
|
Report Metric |
Details |
|
Market Value in 2020 |
US$ 565.6 Million |
|
Market Growth Rate (from 2020 to 2028) |
3.7% |
|
Historical Data |
2018 & 2019 |
|
Base Year |
2020 |
|
Forecast Period |
2020 - 2028 |
|
Units Considered |
Value (US$ Million) |
|
Market Segments |
By Exposure, By Source, By Diagnosis, By Treatment, By Route Of Administration, And By Application |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). |
|
Key Companies Profiled |
Eli Lilly and Company |
|
Customization Scope |
Report customization available on request |
|
Pricing and Purchase Options |
Avail tailor-made purchase options to meet your research requirements. |
Target Audience
- Supply-side: Manufacturers, raw material suppliers, and distributors
- Demand Side: Ambulatory surgery centers (ASCs), Hospitals, Research Institutes, And Long-Term Care Centers
- Regulatory Side: Concerned government authorities, commercial research & development (R&D) institutions, and other regulatory bodies.
- Associations and Industry Bodies: Center for Biologics Evaluation and Research (CBER), U,S. Food & Drug Administration (FDA), European Monetary System (EMS), among others.